Stem cells are frozen by adding a cryoprotective solution, cooling them under controlled conditions, and transferring them to cryogenic storage. Many blood-forming and mesenchymal stromal-cell protocols use about 10% dimethyl sulfoxide (DMSO) and cooling near 1°C per minute, followed by storage in liquid or vapor-phase nitrogen. The exact method depends on the cell type and product. This preservation process is called cryopreservation .
Before the cells are used, staff thaw them according to the product instructions and assess their quality. Freezing can preserve cells for later use; it does not establish whether a treatment will work for a particular disease .

Why cells need protection
Putting living cells into an ordinary freezer is not enough. Ice formation can damage cell structures, while the remaining unfrozen liquid becomes more concentrated and causes osmotic stress. A cryoprotective solution and an appropriate cooling rate help limit these injuries .
DMSO is a commonly used cryoprotectant that can enter cells. Other agents include glycerol, ethylene glycol, and propylene glycol. Substances such as sucrose, trehalose, polyethylene glycol, and polyvinylpyrrolidone act mainly outside the cells. Which agents are used, and at what concentration, must fit the protocol .
The freezing process
The preservation pathway includes preparation, freezing, storage, and checks after thawing. These stages are distinct from collection and treatment administration in the wider stem cell treatment process in Japan.
| Stage | What staff do | What needs documenting |
|---|---|---|
| Assess the batch | Confirm identity, cell counts, viability, and relevant contamination-test information. | The batch identifier and its pre-freeze quality results. |
| Add protective solution | Combine the cells with the protocol-specific freezing fluid. | The ingredients, concentrations, and handling conditions. |
| Control cooling | Use the cooling method appropriate to that cell type and product. | The specified cooling profile, rather than just a final temperature. |
| Maintain storage | Keep the containers under the required cryogenic conditions. | Storage conditions and traceability records. |
| Thaw and prepare | Follow the product instructions, including dilution or washing where specified. | The preparation method and permitted time before use. |
| Assess after thawing | Perform the required quality checks and review the results against product-specific criteria. | The recovered cell count, viability, and other required quality information. |
Cooling and thawing affect cell survival, and post-thaw viability and function need assessment . The licensed cord-blood label discussed below specifies post-thaw sampling for quality-control tests, including cell counts, viability, and sterility, according to transplant-center procedures . Not every test has an immediate result, so ask which results are available before use and how pending results are handled.
In the United States, FDA’s 2008 notice on somatic-cell therapy guidance describes chemistry, manufacturing, and control information submitted with an investigational new drug application. This is a manufacturing-review context, not proof of clinical benefit or approval of a private clinic’s service .
Cooling rates and vitrification
Controlled slow freezing and vitrification are not interchangeable terms. In slow-freezing protocols, gradual cooling helps manage water movement and ice-related injury. Vitrification instead aims to produce a glass-like solid without ice crystallization, using a suitable combination of cryoprotectants and cooling conditions .
The commonly cited combination of 10% DMSO and cooling near 1°C per minute is a general pattern, not a universal recipe or a guarantee that the sample has vitrified. DMSO can also be toxic, so adding more is not automatically safer .
The cell type changes the method
The Whaley review describes slow cooling as generally suitable for hematopoietic, or blood-forming, stem cells and mesenchymal stromal cells. It also discusses rapid-cooling approaches for embryonic stem cells and other sensitive cells. These are broad method comparisons, not instructions to transfer one product’s protocol to another cell type .
Temperatures and product-specific numbers
A concrete example is the U.S.-licensed HPC, Cord Blood product from ClinImmune Labs, University of Colorado Cord Blood Bank. It contains donor-derived blood-forming progenitor cells for hematopoietic and immunologic reconstitution in specified disorders of the blood-forming system. Its DailyMed listing was updated April 10, 2025; the prescribing information displays a June 2012 revision date. These specifications do not apply to mesenchymal or fat-derived cell services .
| Item | Specification | Scope |
|---|---|---|
| Common freezing formulation | About 10% DMSO, sometimes with other agents . | General method pattern; not universal. |
| Common cooling rate | About 1°C per minute . | General method pattern; cell-specific validation matters. |
| Product formulation | 10% DMSO and 1% Dextran 40 at cryopreservation . | This HPC, Cord Blood product only. |
| Product storage | At or below −150°C until thawing and preparation; vapor-phase nitrogen storage is recommended at the transplant center . | This HPC, Cord Blood product only. |
| Unit content at freezing | At least 5 × 108 total nucleated cells, including at least 1.25 × 106 viable CD34+ cells . | This HPC, Cord Blood product only; not a post-thaw count. |
| Recommended minimum dose | 2.5 × 107 nucleated cells per kg, measured at cryopreservation . | This HPC, Cord Blood product only; clinical selection is a transplant-team decision. |
| Prepared-product handling | 1–8°C for up to 4 hours after preparation for infusion; the recommended DMSO administration limit is 1 gram per kg per day . | This HPC, Cord Blood product only; not a long-term storage temperature. |
The cell-content and dose figures above are measured at cryopreservation. They must not be presented as guaranteed post-thaw cell counts. Likewise, the short refrigerated holding period after preparation is separate from long-term cryogenic storage .
Storage and batch records
Cryopreservation allows cells to be banked for later research or medical use . Whether a stored batch can supply a later treatment depends on the required dose and its quality after thawing; storage does not guarantee that another collection will never be needed.
When discussing a cell processing center in Japan, ask who maintains the storage records and who authorizes release. Request the batch ID, cell type, freeze date, number of containers, storage conditions, pre-freeze counts, and passage history if the cells were expanded. Also establish ownership, storage fees, and what happens if the batch cannot be used.
The distinction between autologous and donor-derived cells belongs in those records. Ask whether the stored cells are yours or a donor’s rather than assuming that all frozen-cell products follow the same pathway.
Thawing, testing, and safety
Staff should follow the applicable product instructions for thawing, dilution, washing, and the time allowed before administration. The cord-blood example includes instructions for preparation and post-thaw quality-control sampling; these are not a home-thawing procedure or a protocol for other cell products .
A high cell count before freezing does not tell you how many viable cells will be available after thawing.
Ask for both the recovered viable-cell count and the viability percentage, together with any required functional or potency assessment. A percentage alone does not tell you the total usable dose. The method review emphasizes assessing both viability and function after thawing .
The cord-blood label reports infusion-reaction data from the COBLT single-arm trial or expanded-access use: 442 infusions from multiple cord-blood banks, in a population that was 60% male with a median age of 5 years (range 0.05–68). Patients had hematologic malignancies, inherited metabolic disorders, primary immunodeficiencies, or bone marrow failure. Serious cardiopulmonary reactions occurred at a reported rate of 0.8%; common reactions included hypertension, vomiting, nausea, and bradycardia .
Those are transplant-infusion data, not an estimate of harm caused by freezing alone. Preparative regimens and graft-versus-host disease prevention were not standardized, and the findings cannot establish the safety of unrelated cell products or clinic services . Questions about stem cell therapy safety in Japan therefore need to identify the actual product, proposed use, and administration plan.
What freezing cannot establish
- Clinical benefit. Preserving viable cells does not demonstrate that they improve a disease. Assess the evidence for the proposed use separately from storage quality .
- Interchangeability. Cell type, formulation, cooling conditions, and thawing methods differ; one successful preservation protocol does not validate another .
- Regulatory approval. Japan’s regenerative-medical-product approval information is distinct from the provision-plan procedures under the Act on the Safety of Regenerative Medicine. A submitted plan or filing number is not a product marketing authorization or proof of treatment benefit .
When discussing indications and contraindications in Japan, ask whether the proposed intervention is an approved product used for its authorized indication, an experimental intervention, or a private clinical service. Do not use a storage certificate or trial registration as a substitute for disease-specific evidence.
How to check a proposed freezing plan
Consider a practical document-checking scenario: a clinic gives you a pre-freeze cell count and says the cells will be available for later use. The cord-blood label illustrates the missing distinction: its stated cell content is measured at cryopreservation, while its preparation instructions separately call for post-thaw quality-control sampling . Ask what will be measured after thawing, what criteria apply, and what happens if recovery is insufficient. This is a document-based example, not a report of a patient’s outcome.
Use these questions when you compare hospitals in Japan:
- What exact cell type and source will be stored?
- Which protective solution and cooling method have been selected for that product?
- What are the pre-freeze cell count, viability, contamination-test results, and expansion history?
- What storage conditions apply, and who maintains the records?
- Which post-thaw counts, viability measurements, and other quality checks are required?
- Which results are available before administration, and how are pending results handled?
- If the batch is unsuitable or the recovered dose is insufficient, what are the next steps, costs, and alternatives?
Questions about a proposed cell-storage plan?
Ask which batch records, storage terms, and post-thaw quality results would be provided before you agree to storage or treatment.
Bottom line: Freezing stem cells means using an appropriate protective solution, controlled cooling, and cryogenic storage, followed by product-specific thawing and quality checks. The key question is not just whether the cells were frozen, but whether the recovered batch is suitable for its intended use .
References:
[1] Whaley D et al. Cryopreservation: An Overview of Principles and Cell-Specific Considerations. Cell Transplantation, 2021. University of California Irvine-affiliated authors; full text hosted by NIH/NLM.
[2] NLM DailyMed. HPC, Cord Blood — ClinImmune Labs, University of Colorado Cord Blood Bank. Listing updated April 10, 2025; prescribing information revised June 2012.
[3] FDA. Federal Register notice announcing guidance on Chemistry, Manufacturing, and Control Information for Human Somatic Cell Therapy Investigational New Drug Applications. April 10, 2008.
[4] PMDA. Regenerative Medical Products — approved information.
[5] Japanese Law Translation, Ministry of Justice. Act on the Safety of Regenerative Medicine, including Articles 4 and 5 on provision plans.




